| Ulcerative colitis in adults: a review B Gros, GG Kaplan Jama 330 (10), 951-965, 2023 | 223 | 2023 |
| COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study JL Alexander, NA Kennedy, H Ibraheim, S Anandabaskaran, A Saifuddin, ... The lancet Gastroenterology & hepatology 7 (4), 342-352, 2022 | 143 | 2022 |
| COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre … JL Alexander, Z Liu, DM Sandoval, C Reynolds, H Ibraheim, ... The Lancet Gastroenterology & Hepatology 7 (11), 1005-1015, 2022 | 55 | 2022 |
| Exploring the pipeline of novel therapies for inflammatory bowel disease; state of the art review Y Zurba, B Gros, M Shehab Biomedicines 11 (3), 747, 2023 | 41 | 2023 |
| Area under trough concentrations of tacrolimus as a predictor of progressive renal impairment after liver transplantation M Rodríguez-Perálvarez, M Guerrero, L De Luca, B Gros, D Thorburn, ... Transplantation 103 (12), 2539-2548, 2019 | 23 | 2019 |
| Bile acid malabsorption in patients with chronic diarrhea and Crohn's disease. LM Mena-Bares, JM Benitez-Cantero, E Iglesias-Flores, B Gros-Alcalde, ... Revista Espanola de Enfermadades Digestivas (REED) 111 (1), 40-45, 2019 | 15 | 2019 |
| Real-world cohort study on the effectiveness and safety of filgotinib use in ulcerative colitis B Gros, M Goodall, N Plevris, N Constantine-Cooke, AT Elford, C O’Hare, ... Journal of Crohn's and Colitis 19 (1), jjad187, 2025 | 14 | 2025 |
| Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort B Gros, N Plevris, N Constantine‐Cooke, M Lyons, C O'Hare, C Noble, ... United European Gastroenterology Journal 11 (2), 179-188, 2023 | 14 | 2023 |
| Infliximab and tofacitinib attenuate neutralizing antibody responses against SARS-CoV-2 ancestral and omicron variants in inflammatory bowel disease patients after 3 doses of … Z Liu, JL Alexander, KW Lin, T Ahmad, KM Pollock, N Powell, ... Gastroenterology 164 (2), 300, 2022 | 14 | 2022 |
| Safety, effectiveness, and treatment persistence of subcutaneous vedolizumab in IBD: a multicenter study from the United Kingdom SH Lim, B Gros, E Sharma, A Lehmann, JO Lindsay, L Caulfield, DR Gaya, ... Inflammatory Bowel Diseases 30 (8), 1284-1294, 2024 | 13 | 2024 |
| Real‐world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA‐SWITCH study MJ Casanova, Ó Nantes, P Varela, M Vela‐González, M Rivero, ... Alimentary Pharmacology & Therapeutics 58 (1), 60-70, 2023 | 12 | 2023 |
| Crossing barriers: the burden of inflammatory bowel disease across Western Europe A Kumar, N Yassin, A Marley, V Bellato, C Foppa, G Pellino, P Myrelid, ... Therapeutic advances in gastroenterology 16, 17562848231218615, 2023 | 10 | 2023 |
| Real-world effectiveness of upadacitinib in Crohn’s disease: a UK multicentre retrospective cohort study AT Elford, M Bishara, N Plevris, B Gros, N Constantine-Cooke, ... Frontline Gastroenterology 15 (4), 297-304, 2024 | 9 | 2024 |
| Harms with placebo in trials of biological therapies and small molecules as maintenance therapy in inflammatory bowel disease: a systematic review and meta-analysis B Gros, J Blackwell, JP Segal, CP Black, AC Ford, S Din Lancet Gastroenterology and Hepatology, 2024 | 7 | 2024 |
| Longitudinal fecal calprotectin profiles characterize disease course heterogeneity in Crohn’s disease N Constantine-Cooke, K Monterrubio-Gómez, N Plevris, LAAP Derikx, ... Clinical Gastroenterology and Hepatology 21 (11), 2918-2927. e6, 2023 | 5 | 2023 |
| Impact of Clostridioides difficile infection in patients admitted with ulcerative colitis B Gros, P Soto, M Causse, S Marín, E Iglesias, JM Benítez Scandinavian Journal of Gastroenterology 58 (3), 232-239, 2023 | 5 | 2023 |
| Harms with placebo in trials of biological therapies and small molecules as induction therapy in inflammatory bowel disease: a systematic review and meta-analysis S Din, JP Segal, J Blackwell, B Gros, CP Black, AC Ford Lancet Gastroenterology and Hepatology, 2024 | 4 | 2024 |
| Rates, predictive factors and effectiveness of ustekinumab intensification to 4-or 6-weekly intervals in Crohn's disease LAAP Derikx, N Plevris, S Su, B Gros, M Lyons, SI Siakavellas, ... Digestive and Liver Disease 55 (8), 1034-1041, 2023 | 4 | 2023 |
| Helicobacter species and hepato-biliary tract malignancies: A systematic review and meta-analysis B Gros, A Gómez Pérez, M Pleguezuelo, FJ Serrano Ruiz, M de la Mata, ... Cancers 15 (3), 595, 2023 | 4 | 2023 |
| Neutralising antibody responses against SARS-CoV-2 Omicron BA. 4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine … Z Liu, JL Alexander, K Le, X Zhou, H Ibraheim, S Anandabaskaran, ... EClinicalMedicine 64, 2023 | 3 | 2023 |
Charlie LeesUniversity of Edinburghایمیل تأیید شده در ed.ac.uk
